Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients

Haemophilia

Volumn 13, Issue 5, 2007, Pages 533-541

  Brophy, D F ^a   Martin, E J ^a   Nolte, M E ^a   Kuhn, J G ^a   Carr Jr , M E ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Clot elastic modulus; Haemophilia; NN1731; Platelet contractile force; Recombinant factor VIIa; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; HEMOSTATIC AGENT; NN 1731; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BLOOD CLOT; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE FUNCTION; YOUNG MODULUS;

ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; CLOT RETRACTION; FACTOR VII; FEMALE; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET COUNT;

EID: 34548317168     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01524.x     Document Type: Article

References (21)

1. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia Haemophilia 2006; 12 (Suppl. 3): 52-60.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
3. Siddiqui MA, Scott LJ. Recombinant factor VIIa (Eptacog Alfa): A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs 2005; 65: 1161-77.
4. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-57.
5. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
6. Hoffman M, Monroe D, Roberts H. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S61-5.
7. Monroe D, Hoffman M, Oliver J, Roberts H. Platelet activity of high-dose factor VIIa in independent of tissue factor. Br J Haematol 1997; 99: 542-7.
8. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
9. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
10. Persson E, Bak H, Ostergaard A, Olsen OH. Augmented intrinsic activity of factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J 2004; 2: 497-503.
11. Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol 2004; 1 (Suppl. 1): 89-92.
12. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-8.
13. Allen GA, Persson E, Campbell A, Ezban M, Hedner U, Wolberg AS. A Variant of recombinant factor VIIa with enhanced Procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Artherioscler Thromb Vasc Biol 2007; 27: 683-9.
14. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/ M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137 (2): 158-65.
15. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-20.
16. Carr ME, Martin EJ, Kuhn JG, Spiess BD. Onset of force development as a marker of thrombin generation in whole blood: The thrombin generation time (TGT). J Thromb Haemost 2003; 1: 1977-83.
17. Carr ME Jr. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003; 38: 55-78.
18. Carr ME Jr, Martin EJ, Kuhn JG, Ambrose H, Fern S, Bryant PC. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa. Clin Lab 2004; 505: 29-38.
19. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
20. Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003; 89: 803-11.
21. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LV. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-46.